Top View
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
- A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101), a BH3 Mimetic, in Patients with Advanced Adrenal Cortical Carcinoma
- High-Dose Mitotane Strategy in Adrenocortical Carcinoma
- Pharmacological Profile and Effects of Mitotane In
- Network Chemotherapy Protocols
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Subacute Cutaneous Lupus Erythematosus Induced by Mitotane
- LCA Oral SACT Counselling Handbook
- Temozolomide Therapy: Focus on Patients with Pituitary Carcinoma
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- MANUAL for Medical Facilities
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- Longitudinal Trends in Use and Costs of Targeted Therapies for Common Cancers in Taiwan: a Retrospective Observational Study
- Etoposide, Doxorubicin and Cisplatin Plus Mitotane in the Treatment of Advanced Adrenocortical Carcinoma: a Large Prospective Phase II Trial
- Drug Interactions Adjuvant Therapy for Breast Cancer Using UBRAJCAF ; Cyclophosphamide, Doxorubicin and Updated in Precautions Fluorouracil
- Phase II Study of Weekly Paclitaxel and Sorafenib As Second/Third-Line
- Advanced Adrenocortical Carcinoma –
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Mitomycin (Systemic): Drug Information
- Study Protocol);
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- Activity and Safety of Temozolomide.Pdf
- University of Birmingham Mitotane Treatment in Patients with Metastatic
- LYSODREN (Mitotane Tablets, USP) Should Be Administered Under the Supervision of a Qualified Physician Experienced in the Uses of Cancer Chemotherapeutic Agents
- Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer
- Chemotherapy for Advanced Adrenal Cancer
- Eclinicalworks Lab and Radiology Compendiums June 2007
- Medical Approaches in Adrenocortical Carcinoma
- BC Cancer Protocol Summary for Treatment of Metastatic Adrenocortical Cancer with Etoposide, Doxorubicin, Cisplatin and Mitotane
- Adrenocortical Carcinoma1
- Mitotane Concentrations Influence the Risk of Recurrence In
- What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? an Unanswered Question
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
- NIOSH Alert: Preventing Occupational Exposures to Antineoplastic
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Adverse Mucocutaneous Reactions Related to Chemothera- Peutic Agents – Part II Reações Tegumentares Adversas Relacionadas Aos Agentes Antineoplásicos – Parte II
- Activity and Safety of Temozolomide in Advanced Adrenocortical Carcinoma Patients
- Activity and Safety of Temozolomide in Advanced Adrenocortical Carcinoma Patients with Disease Progression to Standard Chemotherapy Plus Mitotane
- Do Not Tube List
- Topical Application of Mitomycin C in Functional Endoscopic Sinus Surgery Roby T Koshy1, Surianarayanan Gopalakrishnan2, Padmanabhan Karthikeyan3
- Docetaxel: Drug Information
- Supplementary Online Content
- Hazardous Drug List
- Resolution Ap (2000) 1
- Medications That Are Considered Hazardous
- DRUG NAME: Mitotane
- Antineoplastic Drugs